MGMT and glioblastoma: For patients in the GBM group, the mean age was 63 years (range: 31–79), mean overall survival time was 386 days, 5 patients were female (36%) and 9 patients were male (64%) and the distribution of MGMT promotor methylation status was 50% unmethylated and methylated.